Dyspnoea score ‐ not measured · adults with acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent PE · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in PE: recurrent fatal and non‐fatal PE, demonstrated by CT, pulmonary… compared with anticoagulation (moderate certainty).
1 finding from 1 review
Mortality (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in mortality (up to 6 months) compared with anticoagulation (moderate certainty).
1 finding from 1 review
Symtomatic lower extremity venous thrombosis confirmed by Doppler ultrasound or venography (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in symtomatic lower extremity venous thrombosis confirmed by Doppler… compared with anticoagulation (moderate certainty).
1 finding from 1 review
Filter‐related complications (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
1 finding from 1 review
Major bleeding · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in major bleedingc (up to 6 months) compared with anticoagulation (moderate certainty).
1 finding from 1 review
Change in weight (kg) · adults and children with cystic fibrosis
1 finding from 1 review
Change in height · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in BMI · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of bowel symptoms: stool frequency · adults and children with cystic fibrosis
1 finding from 1 review
CFA: FFE (g/day) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall mortality · alcohol consumers with high blood pressure
The intervention showed no clear difference in overall mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular events · alcohol consumers with high blood pressure
It is very uncertain whether the intervention changes cardiovascular events (very low certainty).
1 finding from 1 review
Intervention not reported
Decrease in systolic blood pressure (mmHg) · alcohol consumers with high blood pressure
1 finding from 1 review
Intervention not reported
Decrease in diastolic blood pressure (mmHg) · alcohol consumers with high blood pressure
1 finding from 1 review
Intervention not reported
Decrease in alcohol intake (g) · alcohol consumers with high blood pressure
1 finding from 1 review
Intervention not reported
Proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg · alcohol consumers with high blood pressure
It is very uncertain whether the intervention changes proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg (very low certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower CVD compared with placebo (high certainty).
1 finding from 1 review